Boston-based startup Legato emerged from stealth Wednesday to announce $12 million [1] in funding and preview its AI-powered hearing-assist glasses.
The launch signals a shift toward integrating assistive hearing technology into wearable eyewear, potentially reducing the stigma associated with traditional hearing aids.
The company's new product, called Legato Frames, utilizes artificial intelligence to provide hearing assistance to users. By embedding the technology into glasses, Legato aims to capture a share of the global hearing-device market, which is valued at $15 billion [4].
Legato is headquartered in Boston, Massachusetts. The startup's emergence from stealth follows a period of private development focused on combining AI with audio hardware to improve how users interact with their environment.
The $12 million [1] investment will support the company as it moves toward bringing Legato Frames to market. While traditional hearing aids focus primarily on amplification, the AI-driven approach used by Legato is designed to enhance auditory clarity through software-driven processing.
The global hearing-device market remains a high-growth sector as aging populations and increased awareness of auditory health drive demand [4]. Legato enters this space as a challenger to established medical device manufacturers by positioning its product as a piece of consumer tech.
Company representatives said the goal is to make hearing assistance more accessible and less intrusive. By utilizing the form factor of glasses, the startup intends to streamline the user experience, and integrate the device into daily fashion.
“Legato emerged from stealth Wednesday to announce $12 million in funding.”
The entry of AI-driven wearables into the hearing-assistance space suggests a convergence between medical devices and consumer electronics. By moving hearing technology from the ear canal to the frames of glasses, Legato is attempting to pivot the product from a corrective medical necessity to a lifestyle accessory, which could expand the total addressable market beyond those with diagnosed clinical hearing loss.
